Celsion Corp
Change company Symbol lookup
Select an option...
CLSN Celsion Corp
BAC Bank of America Corp
GPHBF Graphene 3D Lab Inc(British Columbia)
ITRI Itron Inc
LTTTX MFS Lifetime 2025 Fund Class R3
HLI Houlihan Lokey Inc
KICK Master Glazier's Karate International Inc
VIRT Virtu Financial Inc
FB Facebook Inc
ED Consolidated Edison Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Closing Price
$0.87
Day's Change
-0.03 (-3.33%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.9199
Day's Low
0.854
Volume
(Light)
Volume:
3,060,855

10-day average volume:
4,281,050
3,060,855

Kimberly-Clark raised 2020 sales growth outlook to 2%-3% from 1%-2%

7:33 am ET October 22, 2020 (MarketWatch)
Print

(END) Dow Jones Newswires

October 22, 2020 07:33 ET (11:33 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.